{"url_path":"/sec/insm/8-k/2026-07-16/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 —","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1104506/0001140361-26-028602-index.html","accession_number":"0001140361-26-028602","cik":"0001104506","ticker":"INSM","issuer_name":"INSMED Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1104506/0001140361-26-028602-index.html","primary_entity_key":"0001104506","primary_entity_name":"INSMED Inc"},"word_count":199,"has_tables":true,"body_markdown":"ITEM 7.01  —\n\nRegulation FD Disclosure.\n\nOn July 16, 2026, Insmed Incorporated (the “Company”) issued a press release announcing 12-month safety and efficacy data from its ongoing open-label extension study of treprostinil palmitil inhalation powder in patients with\npulmonary arterial hypertension (the “OLE Study”). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.\n\nThe Company will host a conference call to discuss the 12-month data of the OLE Study on July 16, 2026, at 8:00 a.m., Eastern Time, and a live webcast of\nthe call will be available through the investor relations section of the Company’s website. A copy of the slide presentation to be used by the Company during the conference call is attached hereto as Exhibit 99.2 and incorporated herein by reference.\n\nThe information contained in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities\nExchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."}